

12/20/2022

## Essential Health Benefit Formulary Updates

November 2022

The changes below are reflective of OptumRx P&T Committee decisions.

### 2022 FORMULARY CHANGES

Therapeutic Class	Medication	Formulary Changes	Effective Date
Genetic or Enzyme or Protein Disorder: Replacement, Modifiers, Treatment	<b>Tegsedi Injection 284mg/1.5mL</b>	Add QL	1/1/2024

### YEAR-TO-DATE FORMULARY GENERIC RELEASES

Generic drug is available at copay listed once drug is available on the market

Therapeutic Class	Generic Name	For Brand Name	Formulary Status	Available Date
Respiratory Tract/Pulmonary Agents	<b>roflumilast tablets</b>	Daliresp tablets	Tier 1 PA	10/19/2022
Hormonal Agents (Estrogens)	<b>estradiol transdermal gel</b>	Divigel gel	Tier 1	9/30/2022
Multiple Sclerosis Agents	<b>fingolimod Hcl capsules 0.5mg</b>	Gilenya capsules 0.5mg	Tier 4 PA QL	9/23/2022
Antipsychotics	<b>Olanzapine inj 10mg</b>	Zyprexa Inj 10mg	Tier 3	9/1/2022
Antidepressants	<b>vilazodone HCL tab</b>	Viibryd tab	Tier 1 PA, QL	6/2/2022

#### Key

PA= Prior Authorization AL= Age Limit ST= Step Therapy QL=Quantity Limit NF=Non-formulary CM=Oral Chemo Tier 1=preferred generic; Tier 2=preferred brand; Tier 3= Non-preferred brand/generic; Tier 4= Specialty

When generics become available on the EHB formulary, the brand moves to Excluded status. Drugs may be subject to coverage requirements or limits such as prior authorization. Refer to your formulary or plan documents for additional information.

This list does not guarantee coverage.

## YEAR-TO-DATE FORMULARY GENERIC RELEASES

Generic drug is available at copay listed once drug is available on the market

Therapeutic Class	Generic Name	For Brand Name	Formulary Status	Available Date
Genitourinary Agents	<b>fesoterodine fumarate tab ER</b>	Toviaz tab	Tier 1	6/28/2022
Retinoids- Chemotherapy Agents	<b>bexarotene gel 1%</b>	Targretin gel 1%	Tier 4 PA	5/24/2022
Antineoplastics	<b>sorafenib tab 200mg</b>	Nexavar tab 200mg	Tier 4	6/1/2022
Inflammatory Bowel Disease Agents	<b>mesalamine cap 500mg ER</b>	Pentasa cap 500mg ER	Tier 1	5/19/2022
Antibacterials	<b>cefazolin injection 2gm</b>	Kefzol injection	Tier 1	3/21/2022
Anticonvulsants	<b>lacosamide tab</b>	Vimpat tab	Tier 3	3/17/2022
Dermatological Agents	<b>diflorasone cream 0.05%</b>	Psorcon cream 0.05%	Tier 3	3/7/2022
Antifungals	<b>amphotericin injections 50mg</b>	Ambisome injection 50mg	Tier 3	2/17/2022
Genetic or Enzyme Disorder: Replacement Modifiers, Treatment	<b>betaine anhydrous powder</b>	Cystadane powder	Tier 4	1/1/2022
Antiparkinson Agents	<b>carbidopa-levodopa-entacapone</b>	Stalevo	Tier 1	2/25/2022
Antivirals	<b>maraviroc tablets</b>	Selzentry	Tier 1 PA	2/7/2022
Ophthalmic Agents	<b>cyclosporine 0.05% emulsion</b>	Restasis	Tier 1 PA	2/4/2022
Hormonal Agents - Pituitary	<b>vasopressin IV solution 20 unit/mL</b>	Vasostriect	Tier 1	1/14/2022
Gastrointestinal Agents	<b>glycopyrrolate oral solution 1mg/5mL</b>	Cuvposa	Tier 1	1/4/2022
Anti-Addiction/ Substance Abuse Treatment Agents	<b>naloxone nasal spray</b>	Narcan	Tier 1	12/22/2021

### Key

PA= Prior Authorization AL= Age Limit ST= Step Therapy QL=Quantity Limit NF=Non-formulary CM=Oral Chemo Tier 1=preferred generic; Tier 2=preferred brand; Tier 3= Non-preferred brand/generic; Tier 4= Specialty

When generics become available on the EHB formulary, the brand moves to Excluded status. Drugs may be subject to coverage requirements or limits such as prior authorization. Refer to your formulary or plan documents for additional information.

This list does not guarantee coverage.

## YEAR-TO-DATE FORMULARY GENERIC RELEASES

Generic drug is available at copay listed once drug is available on the market

Therapeutic Class	Generic Name	For Brand Name	Formulary Status	Available Date
Dermatological Agents	<b>adapalene-benzoyl peroxide gel 0.3-2.5%</b>	Epiduo Forte	Tier 1	12/1/2021
Electrolytes/ Minerals/ Metals/ Vitamins	<b>carglumic soluble 200mg</b>	Carbaglu	Tier 4	12/16/2021

## YEAR-TO-DATE FORMULARY CHANGES

Therapeutic Class	Medication	Formulary Changes	Effective date
Gastrointestinal Agents	<b>Suprep Bowel Sol Prep Kit</b>	Excluded	1/1/2024
Antineoplastics	<b>Imbruvica suspension 70mg/mL</b>	Tier 4 PA	10/4/2022
Cystic Fibrosis Agents	<b>Orkambi granules 75-94mg</b>	Tier 4 PA QL	9/27/2022
Analgesics	<b>Duramorph inj 0.5mg/mL</b>	Excluded	1/1/2024
Antibacterials	<b>Vandazole gel 0.75%</b>	Excluded	1/1/2024
Blood Products and Modifiers	<b>Pradaxa caps</b>	Excluded QL	1/1/2024
Dermatological Agents	<b>Crotan lot 10%</b>	Excluded	1/1/2024
Electrolytes/Minerals/ Metals/ Vitamins	<b>Virt-Nate cap DHA</b>	Excluded	1/1/2023
Miscellaneous Therapeutic Agents	<b>Argyl Saline solution 0.9% irrigation</b>	Excluded	1/1/2023
	<b>Curity Saline solution 0.9% irrigation</b>	Excluded	1/1/2023
Diabetes- Glucose Monitoring	<b>CeQur Simpl Kit Patch 2U</b>	Tier 2	9/1/2022
	<b>CeQur Simpl Kit Starter</b>	Tier 2	9/1/2022

### Key

PA= Prior Authorization AL= Age Limit ST= Step Therapy QL=Quantity Limit NF=Non-formulary CM=Oral Chemo Tier 1=preferred generic; Tier 2=preferred brand; Tier 3= Non-preferred brand/generic; Tier 4= Specialty

When generics become available on the EHB formulary, the brand moves to Excluded status. Drugs may be subject to coverage requirements or limits such as prior authorization. Refer to your formulary or plan documents for additional information.

This list does not guarantee coverage.

## YEAR-TO-DATE FORMULARY CHANGES

Therapeutic Class	Medication	Formulary Changes	Effective date
Miscellaneous Therapeutic Agents	<b>Botox Injection 100unit, 200unit</b>	Tier 3 DA	1/1/2023
	<b>Omnipod</b>	Tier 2	9/1/2022
Antineoplastics – Drugs for Cancer	<b>Enhertu injection 100mg</b>	Tier 4 PA	9/1/2022
Antipsychotics- Drugs for Mood Disorders	<b>quetiapine tab 150mg</b>	Tier 1 QL	8/4/2022
Dermatological Agents – Skin Agents	<b>Cibinqo tab</b>	Tier 4 PA, QL	8/1/2022
Diabetes- Glucose Monitoring	<b>CeQur Simpl Kit Starter</b>	Tier 2	9/1/2022
Immunological Agents- Drugs for Immune System Stimulation or	<b>Skyrizi Solution 60mg/mL Injection 150mg/mL</b>	Tier 4 PA	8/9/2022
Anticoagulants–Blood Thinners	<b>Enoxaparin Inj</b>	Tier 3 QL	1/1/2023
	<b>Fondaparinux Inj</b>		
Anti-hepatitis B (HBV) Agents	<b>Baraclude sol</b>	Tier 3 QL	1/1/2023
	<b>Entecavir tab</b>	Tier 1 QL	
Anti-HIV Agents	<b>Epivir HBV Sol 5mg/mL</b>	Tier 3	1/1/2023
	<b>lamivudine tab 100mg</b>	Tier 1	
Antineoplastics	<b>Enhertu inj 100mg</b>	Tier 4 PA	9/1/2022
	<b>Rubraca tab</b>	Excluded PA	1/1/2024
Antivirals	<b>adefov dipivoxil tab 10mg</b>	Tier 3	1/1/2023

### Key

PA= Prior Authorization AL= Age Limit ST= Step Therapy QL=Quantity Limit NF=Non-formulary CM=Oral Chemo Tier 1=preferred generic; Tier 2=preferred brand; Tier 3= Non-preferred brand/generic; Tier 4= Specialty

When generics become available on the EHB formulary, the brand moves to Excluded status. Drugs may be subject to coverage requirements or limits such as prior authorization. Refer to your formulary or plan documents for additional information.

This list does not guarantee coverage.

## YEAR-TO-DATE FORMULARY CHANGES

Therapeutic Class	Medication	Formulary Changes	Effective date
Anticoagulants	<b>Enoxaparin injection</b>	Tier 3 QL	1/1/2023
	<b>Fondaparinux injection</b>	Tier 3 QL	1/1/2023
Dermatological Agents-Skin Agents	<b>Botox Inj 100 unit, 200 unit</b>	Tier 3 PA	1/1/2023
	<b>Cibinqo Tab</b>	Tier 4 PA, QL	8/1/2022
Antibacterials	<b>Xifaxan tab 200mg</b>	Excluded PA	1/1/2024
Anticoagulants	<b>Pradaxa cap</b>	Tier 3 ST, QL	1/1/2024
Ophthalmic Agents - Drugs for Glaucoma	<b>Phospholine sol 0.125%OP</b>	Tier 3	1/1/2023
Anticonvulsants	<b>levetiracetam/NaCL sol 250/50mL</b>	Tier 1	6/17/2022
Respiratory Tract/Pulmonary	<b>Tyvaso DPI powder</b>	Tier 4 PA, QL	6/28/2022
Hematological Agents	<b>Pyrukynd tab</b>	Tier 4 PA, QL	7/1/2022

### Key

PA= Prior Authorization AL= Age Limit ST= Step Therapy QL=Quantity Limit NF=Non-formulary CM=Oral Chemo Tier 1=preferred generic; Tier 2=preferred brand; Tier 3= Non-preferred brand/generic; Tier 4= Specialty

When generics become available on the EHB formulary, the brand moves to Excluded status. Drugs may be subject to coverage requirements or limits such as prior authorization. Refer to your formulary or plan documents for additional information.

This list does not guarantee coverage.

## YEAR-TO-DATE FORMULARY CHANGES

Therapeutic Class	Medication	Formulary Changes	Effective date
ADHD Agents	<b>amphetamine/ dextroamphetamine tablets</b> <b>amphetamine/ dextroamphetamine ER capsules</b> <b>amphetamine tablets</b> <b>dexmethylphenidate tablets</b> <b>dexmethylphenidate ER capsules</b> <b>dextroamphetamine tablets</b> <b>dextroamphetamine ER capsules</b> <b>methylphenidate chewable &amp; solution</b> <b>methylphenidate capsules &amp; tablets</b>	PA Removed	7/1/2022
Antiasthmatic and Bronchodilator Agents	<b>Nucala injection 40mg/0.4mL</b>	Tier 4 PA, QL	6/21/2022
Endocrine and Metabolic Agents	<b>sodium phenylbutyrate oral powder</b>	Tier 4 PA Added	1/1/2024
Endocrine and Metabolic Agents	<b>sodium phenylbutyrate tablet 500mg</b>	Tier 4 PA Added	1/1/2024
Antineoplastic Enzyme Inhibitors	<b>Jakafi tablet 5mg</b>	Tier 4 - CM QL Added	1/1/2023
Analgesics Anti-Inflammatory	<b>Xeljanz, Xeljanz XR</b>	Tier 4 QL Added	1/1/2023
Ophthalmic Antiglaucoma Agents	<b>brimonidine tartrate-timolol maleate ophth solution 0.2-0.5%</b>	Tier 1	4/15/2022
Immunomodulators	<b>Rinvoq tablet ER</b>	Tier 4 Add QL	1/1/2023
Antidiabetic Agents	<b>Ozempic injection 8mg/3mL</b>	Tier 2 ST, QL	4/19/2022
Central Nervous System Agents	<b>Mayzent pak starter</b>	Tier 4 PA, QL	4/5/2022
	<b>Mayzent tab 1 mg</b>	Tier 4 PA, QL	4/5/2022

### Key

PA= Prior Authorization AL= Age Limit ST= Step Therapy QL=Quantity Limit NF=Non-formulary CM=Oral Chemo Tier 1=preferred generic; Tier 2=preferred brand; Tier 3= Non-preferred brand/generic; Tier 4= Specialty

When generics become available on the EHB formulary, the brand moves to Excluded status. Drugs may be subject to coverage requirements or limits such as prior authorization. Refer to your formulary or plan documents for additional information.

This list does not guarantee coverage.

## YEAR-TO-DATE FORMULARY CHANGES

Therapeutic Class	Medication	Formulary Changes	Effective date
Immunological Agents	<b>Rinvoq tab 45mg ER</b>	Tier 4, PA	4/12/2022
Blood Formation Modifiers	<b>Procrit injection</b>	Tier 4 PA	5/1/2022
Electrolyte/Mineral/Metal Modifiers	<b>deferiprone tablet 1000mg</b> <i>(generic Ferriprox)</i>	Tier 3 PA	2/14/2022
Hemostasis Agents	<b>Nuwiq injection 1500unit</b> <b>Nuwiq kit 1500 unit</b>	Tier 4	2/9/2022
Electrolytes/Mineral /Metals/Vitamins	<b>carglumic acid 200mg tablet</b> <i>(generic Carbaglu)</i>	Tier 4 Add PA	1/1/2023
Antimigraine Agents	<b>Ajovy injection 225mg/1.5 mL</b>	Tier 2 PA, QL	1/1/2023
	<b>Emgality injection 120mg/mL</b>	Excluded	1/1/2023
Antivirals	<b>Vemlidy tablet 25 mg</b>	Excluded	1/1/2023
Gastrointestinal Agents	<b>Dexilant DR capsule 30 mg, 60 mg</b>	Excluded	1/1/2023
Gastrointestinal Agents	<b>dexlansoprazole DR capsule</b> <i>(authorized brand alternative Dexilant) 30 mg, 60 mg</i>	Excluded	1/1/2023
Immunological Agents	<b>Rinvoq tablet 30 mg</b>	Tier 4 PA	2/8/2022
Anticoagulants	<b>Xarelto suspension 1 mg/mL</b>	Tier 2 QL	2/1/2022
Vaccines	<b>Prehevbrio suspension 10 mcg/mL</b>	Tier 2 - Preventive	1/13/2022
COVID-19 Antivirals	<b>Paxlovid</b>	Tier 3 QL	1/1/2022
	<b>Molnupiravir</b>	Tier 3 QL	1/1/2022
Blood Glucose Regulators	<b>Rybelsus</b>	Tier 2 ST, QL	1/1/2022
Anti-Addiction/ Substance Abuse Treatment Agents	<b>Chantix tab</b> <b>Apo-varenicline</b>	Tier 3 - Preventive ST, QL	1/1/2022
Antivirals	<b>Intelence 25mg tablet</b>	Tier 2	1/1/2022

### Key

PA= Prior Authorization AL= Age Limit ST= Step Therapy QL=Quantity Limit NF=Non-formulary CM=Oral Chemo Tier 1=preferred generic; Tier 2=preferred brand; Tier 3= Non-preferred brand/generic; Tier 4= Specialty

When generics become available on the EHB formulary, the brand moves to Excluded status. Drugs may be subject to coverage requirements or limits such as prior authorization. Refer to your formulary or plan documents for additional information.

This list does not guarantee coverage.

## YEAR-TO-DATE FORMULARY CHANGES

Therapeutic Class	Medication	Formulary Changes	Effective date
Genitourinary Agents	<b>Toviaz</b>	Tier 3	1/1/2022
Ophthalmic Agents	<b>Restasis</b>	Tier 2 PA	1/1/2022
Antiparasitics	<b>ivermectin 3mg tablet</b> ( <i>generic Stromectol</i> )	Tier 1 QL	1/1/2022
Hormonal Agents, Stimulant/Replacement/Modifying	<b>Premarin vaginal cream</b>	Tier 2	1/1/2022
Antibacterials	<b>vancomycin 250/5mL</b> ( <i>generic Vancocin</i> )	Tier 3	1/1/2022
Antiparkinson Agents	<b>carbidopa 25mg tablet</b> ( <i>generic Lodosyn</i> )	Tier 3	1/1/2022
Antivirals	<b>abacavir/lamivudine/ zidovudine tablet</b> ( <i>generic Trizivir</i> )	Tier 3	1/1/2022
	<b>emtricitabine/tenofovir tab 100-150, 133-200, 167-250</b> ( <i>generic</i> )	Tier 3	1/1/2022
Cardiovascular Agents	<b>Praluent injection</b>	Excluded	1/1/2022
Dental and Oral Agents	<b>Prevident 0.2% solution</b>	Tier 3	1/1/2022
Electrolytes/ Minerals/ Metals/ Vitamins	<b>deferasirox 90mg, 180mg, 360mg</b> ( <i>generic Jadenu</i> )	Excluded	1/1/2022
Gastrointestinal Agents	<b>dexlansoprazole capsule DR</b> ( <i>authorized brand alternative Dexilant</i> )	Tier 2 QL	12/17/2021

### Key

PA= Prior Authorization AL= Age Limit ST= Step Therapy QL=Quantity Limit NF=Non-formulary CM=Oral Chemo Tier 1=preferred generic; Tier 2=preferred brand; Tier 3= Non-preferred brand/generic; Tier 4= Specialty

When generics become available on the EHB formulary, the brand moves to Excluded status. Drugs may be subject to coverage requirements or limits such as prior authorization. Refer to your formulary or plan documents for additional information.

This list does not guarantee coverage.